| ONCO |
Onconetix, Inc. |
72%
|
Reciprocal relationship from ONCO graph: Reciprocal relationship from MDXH graph: Reciprocal relationship from ONCO graph: Reciprocal relationship from MDXH graph: Reciprocal relationship from ONCO g… |
| TECH |
Bio-Techne Corporation |
72%
|
. The reference to our website is an inactive textual reference only and the information contained in, or that can be accessed through, our website or any other website cited in this annual report is… |
| TECH |
Bio-Techne Corporation |
72%
|
Reciprocal relationship from TECH graph: Reciprocal relationship from MDXH graph: Reciprocal relationship from TECH graph: Reciprocal relationship from MDXH graph: Reciprocal relationship from TECH g… |
| VNRX |
VolitionRx Limited |
72%
|
Reciprocal relationship from VNRX graph: ent or clinical trials do not perform as expected, we may not be able to obtain regulatory clearance or approval or commercialize our products. · We expect to… |
| ALTON-CORPORATE-PLAZA-LLC |
ALTON-CORPORATE-PLAZA-LLC |
62%
|
K. McGarrity dated February 18, 2019* F-1 333-260213 October 13, 2021 4.14 Executive Employment Agreement between MDxHealth, Inc. and John Bellano dated May 21, 2019* F-1 333-260213 October 13, 2021 … |
| AMBRY-GENETICS-CORP |
AMBRY-GENETICS-CORP |
62%
|
en 2029 and 2042. Of these issued patents, 9 cover intellectual property used in our Select mdx test, the last of which expires in 2036, 42 cover intellectual property used in our GPS mdx test, the l… |
| ARI |
Apollo Commercial Real Estate Finance, Inc. |
62%
|
Reciprocal relationship from ARI graph: Reciprocal relationship from MDXH graph: Reciprocal relationship from ARI graph: Reciprocal relationship from MDXH graph: en 2029 and 2042. Of these issued pat… |
| ARIOSA-DIAGNOSTICS-INC |
ARIOSA-DIAGNOSTICS-INC |
62%
|
en 2029 and 2042. Of these issued patents, 9 cover intellectual property used in our Select mdx test, the last of which expires in 2036, 42 cover intellectual property used in our GPS mdx test, the l… |
| AWM-INVESTMENT-COMPANY |
AWM-INVESTMENT-COMPANY |
62%
|
ndependent contractors, consultants, commercial partners, and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with the rules and r… |
| COMPANY-LLC |
COMPANY-LLC |
62%
|
K. McGarrity dated February 18, 2019* F-1 333-260213 October 13, 2021 4.14 Executive Employment Agreement between MDxHealth, Inc. and John Bellano dated May 21, 2019* F-1 333-260213 October 13, 2021 … |
| EXOSOME-DIAGNOSTICS-INC |
EXOSOME-DIAGNOSTICS-INC |
62%
|
. The reference to our website is an inactive textual reference only and the information contained in, or that can be accessed through, our website or any other website cited in this annual report is… |
| GENETIC-TECH-LTD |
GENETIC-TECH-LTD |
62%
|
. 2015) , Genetic Tech. Ltd. v. Merial LLC, 818 F.3d 1369 (Fed. Cir. 2016), and Cleveland Clinic Found. v. True Health Diagnostics, 859 F.3d 1352 (Fed. Cir. 2017), that some diagnostic method claims … |
| GENOMIC-HEALTH-INC |
GENOMIC-HEALTH-INC |
62%
|
ndependent contractors, consultants, commercial partners, and vendors. Misconduct by these parties could include intentional, reckless and negligent conduct that fails to: comply with the rules and r… |
| MDXHEALTH-BV-DELTA-LABORATORIES-LLC |
MDXHEALTH-BV-DELTA-LABORATORIES-LLC |
62%
|
rtain state laws include prohibiting a laboratory from running tests, requiring a laboratory to implement a corrective plan, and imposing civil monetary penalties. HIPAA and Other Privacy Laws The He… |
| MDXHEALTH-INC-EXOSOME-DIAGNOSTICS-INC |
MDXHEALTH-INC-EXOSOME-DIAGNOSTICS-INC |
62%
|
rtain state laws include prohibiting a laboratory from running tests, requiring a laboratory to implement a corrective plan, and imposing civil monetary penalties. HIPAA and Other Privacy Laws The He… |
| MDXHEALTH-SA-EXOSOME-DIAGNOSTICS-INC |
MDXHEALTH-SA-EXOSOME-DIAGNOSTICS-INC |
62%
|
K. McGarrity dated February 18, 2019* F-1 333-260213 October 13, 2021 4.14 Executive Employment Agreement between MDxHealth, Inc. and John Bellano dated May 21, 2019* F-1 333-260213 October 13, 2021 … |
| MDXHEALTH-SA-MDXHEALTH-INC |
MDXHEALTH-SA-MDXHEALTH-INC |
62%
|
rtain state laws include prohibiting a laboratory from running tests, requiring a laboratory to implement a corrective plan, and imposing civil monetary penalties. HIPAA and Other Privacy Laws The He… |
| ORBIMED-ADVISORS-LLC |
ORBIMED-ADVISORS-LLC |
62%
|
it and loss. Research and Development Expenses Research and development expenses increased $4.2 million, or 65% for the year ended December 31, 2024, compared to the year ended December 31, 2023, pri… |
| PROSTATE-CONDITIONS-EDUCATION-CO |
PROSTATE-CONDITIONS-EDUCATION-CO |
62%
|
nt managers and regional sales managers. Our sales efforts are directed towards increasing adoption and utilization of our tests in clinical practice. The strategy entails: ● working with community-b… |
| SUBLEASE-AGREEMENT-EXOSOME-DIAGNOSTICS-INC |
SUBLEASE-AGREEMENT-EXOSOME-DIAGNOSTICS-INC |
62%
|
K. McGarrity dated February 18, 2019* F-1 333-260213 October 13, 2021 4.14 Executive Employment Agreement between MDxHealth, Inc. and John Bellano dated May 21, 2019* F-1 333-260213 October 13, 2021 … |
| USA-LLC |
USA-LLC |
62%
|
ith a clear clinical pathway to accurately identify clinically significant prostate cancer while reducing the use of invasive procedures that are prone to complications. Our GPS mdx test addresses me… |
